2023
Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial
Butt J, Lu H, Kondo T, Bachus E, De Boer R, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial. European Heart Journal 2023, 44: ehad655.949. DOI: 10.1093/eurheartj/ehad655.949.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseHeart failureCOPD statusEjection fractionN-terminal pro-B-type natriuretic peptide levelsHistory of COPDNew York Heart Association functional class IIPro-B-type natriuretic peptide levelsBaseline chronic obstructive pulmonary diseaseIntroduction Chronic obstructive pulmonary diseaseLower systolic blood pressureWorse NYHA functional classEfficacy of dapagliflozinHigher NT-proBNPPrior HF hospitalizationFunctional class IINatriuretic peptide levelsNYHA functional classEffect of dapagliflozinObstructive pulmonary diseaseSystolic blood pressureVentricular ejection fractionStructural heart diseaseHF hospitalizationCardiovascular death
2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.Peer-Reviewed Original ResearchDAPA-HF trialReduced ejection fractionEjection fractionCardiovascular deathAsian patientsHF eventsElevated N-terminal pro-B-type natriuretic peptideNew York Heart Association functional class IIN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionSafety of dapagliflozinFunctional class IIEffect of dapagliflozinVentricular ejection fractionDAPA-HFDrug discontinuationHFrEF patientsPrimary endpointAdverse eventsHeart failurePrespecified outcomesPrimary outcomeNatriuretic peptideSame extent